Debates & Insight
P_and_MA_IMG_840x470
Sponsored

Pricing and market access – facts versus fiction

‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.

Debates & Insight
NICE-logo_16-9
Sponsored

OMA at NICE: Unlocking Access One Year On

A new report by health economist Leela Barham examines how NICE’s Office for Market Access has progressed after a year in operation.

News

Press Releases

Views & Analysis

Newsletters and Deep Dive
digital magazine

Webinars

Podcasts

Video

White Papers

Spotlight on
Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Debates & Insight
PMA 2015 2016
Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Debates & Insight

Partner Content